See What HealthDay Can Do For You
Contact Us

FDA Adds Warning to Zanaflex Label

Coadministering Zanaflex with CYP1A2 inhibitors could increase its sedative effects

FRIDAY, April 13 (HealthDay News) -- The U.S. Food and Drug Administration has changed the label for the spasticity drug Zanaflex (tizanidine hydrochloride) to warn that its use is contraindicated in patients taking fluvoxamine, ciprofloxacin or other CYP1A2 inhibitors due to a potentially dangerous increase in the risk of sedation and hypotension.

"Although there are no clinical studies evaluating the effects of other CYP1A2 inhibitors on tizanidine, coadministration of tizanidine with other CYP1A2 inhibitors (zileuton, other fluroquinolones, antiarrythmics, cimetidine, famotidine, oral contraceptives, acyclovir and ticlopidine) should be avoided," the FDA cautions.

Zanaflex is made by Acorda Therapeutics.

More Information - FDA
More Information - Acorda Letter

Physician's Briefing


HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.